Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV.
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, Antinori A; Vax ICONA ORCHESTRA Study group. Vergori A, et al. Among authors: gagliardini r. Int J Infect Dis. 2024 Apr 19:107065. doi: 10.1016/j.ijid.2024.107065. Online ahead of print. Int J Infect Dis. 2024. PMID: 38643867
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. Among authors: gagliardini r. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
FINDINGS TO DATE: The open-ended cohort has been used to assess (1) prognosis in terms of survival or development of AIDS-related or non-AIDS-related clinical events; (2) long-term efficacy and safety of different antiretroviral regimens and (3) virological and immunologic …
FINDINGS TO DATE: The open-ended cohort has been used to assess (1) prognosis in terms of survival or development of AIDS-related or non-AID …
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, Antinori A; Mpox Vaccine Lazio Study Group. Mazzotta V, et al. Among authors: gagliardini r. EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38292040 Free PMC article.
MVA-BN was safe as well tolerated, with grade 2 reactogenicity higher after the first administration in vaccine-naive than in vaccine-experienced individuals, but with no evidence for a difference in the duration of these adverse effects. Further studies are needed to evaluate th …
MVA-BN was safe as well tolerated, with grade 2 reactogenicity higher after the first administration in vaccine-naive than in vaccine-experi …
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.
Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, Mazzotta V, Colavita F, Fusto M, Cimini E, Notari S, D'Aquila V, Lanini S, Lapa D, Gagliardini R, Mariotti D, Giannico G, Girardi E, Vaia F, Agrati C, Maggi F, Antinori A. Vergori A, et al. Among authors: gagliardini r. Vaccines (Basel). 2023 Nov 22;11(12):1739. doi: 10.3390/vaccines11121739. Vaccines (Basel). 2023. PMID: 38140145 Free PMC article.
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.
D'arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. D'arminio Monforte A, et al. J Antimicrob Chemother. 2023 Apr 3;78(4):933-945. doi: 10.1093/jac/dkad026. J Antimicrob Chemother. 2023. PMID: 36775983
OBJECTIVES: To compare the long-term risk of treatment failure of dolutegravir-based ART in men and women in a real-life setting. ...
OBJECTIVES: To compare the long-term risk of treatment failure of dolutegravir-based ART in men and women in a real-life setting. ...
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N. Modica S, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2020 Jan 1;75(1):194-199. doi: 10.1093/jac/dkz424. J Antimicrob Chemother. 2020. PMID: 31605107
Although we did not detect a detrimental effect of past NRTI resistance in virologically suppressed patients, a fully active regimen remains preferred in this setting due to possible rebound of drug-resistant virus in the long term....
Although we did not detect a detrimental effect of past NRTI resistance in virologically suppressed patients, a fully active regimen remains …
[Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Giordani B, Amato A, Majo F, Ferrari G, Quattrucci S, Minicucci L, Padoan R, Floridia G, Salvatore D, Carnovale V, Puppo Fornaro G, Taruscio D, Salvatore M; Gruppo di lavoro RIFC. Giordani B, et al. Epidemiol Prev. 2019 Jul-Aug;43(4S1):1-36. doi: 10.19191/EP19.4.S1.067. Epidemiol Prev. 2019. PMID: 31370382 Free article. Italian.
In particular, the Report should contribute to the following objectives: * to analize medium- and long-term clinical and epidemiological trends of the disesase; * to identify the main health care needs at regional and national level in order to contribute to the healthcare …
In particular, the Report should contribute to the following objectives: * to analize medium- and long-term clinical and epidemiologi …
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients.
Antinori A, Santoro MM, Gagliardini R, Marchetti G, Mondi A, Cento V, Perno CF, Andreoni M; Two-Drug Antiretroviral Regimens expert panel. Antinori A, et al. Among authors: gagliardini r. New Microbiol. 2019 Apr;42(2):69-80. Epub 2019 Feb 20. New Microbiol. 2019. PMID: 30785209 Free article. Review.
New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral- …
New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. …
15 results